Global Healthcare Completes Cancer Diagnosis M&A, Q1 Performance Remains Resilient

Abbott Laboratories (ABT) reported first-quarter 2026 revenues of about $11.2 billion—up roughly 7% year-over-year—and adjusted EPS growth of 6%. On March 23, the company closed its acquisition of Exact Sciences for approximately KRW 20 trillion (around $15 billion), adding a new oncology-focused diagnostics segment and estimating a $0.20 per-share dilution to 2026 adjusted EPS. Abbott reiterated low-single-digit full-year revenue growth guidance, issued second-quarter adjusted EPS guidance, and declared a $0.63 quarterly dividend payable May 15, extending its dividend streak to 409 consecutive quarters.

While Abbott continues to deny liability in U.S. shareholder derivative suits tied to its infant formula recall, it has entered settlement discussions contingent on enhanced governance and compliance measures. Plaintiff counsel plans to seek court approval of approximately $15.85 million in fees and expenses (about KRW 20 billion). Director Daniel J. Starks further increased his stake in late April through open-market purchases and stock awards, bringing his direct holdings to over $600 million (roughly KRW 800 billion) at current share prices.

In its Q1 earnings release and external communications, Abbott has repeatedly emphasized its plan to reignite diagnostics growth via the newly integrated oncology portfolio, targeting double-digit diagnostic revenue growth and several billion dollars in incremental 2026 sales. In diabetes care, sales of the FreeStyle Libre continuous glucose monitoring system approached $2 billion for the quarter, with strong sensor-based device performance bolstering overall results.

Abbott is a global healthcare company spanning nutrition, diagnostics, branded generics and medical devices, with diagnostic and sensor platforms—such as cardiovascular devices and continuous glucose monitors—serving as core growth drivers. Its strategy to expand early cancer detection and chronic-disease management solutions aligns with broader industry trends fueled by aging populations and rising chronic-disease prevalence in the high-growth global diagnostics and medical-device markets.